If it gets approved in the future, weight loss results from this drug can still look different depending on lifestyle changes, starting point, and individual response
Tip: Rotate injection sites to minimize irritation
Kim Connelly, MMBS, PhD, FRCPC Staff Cardiologist, St
Supporting this, in a phase 2a trial in people with MASLD, the dual GLP-1/GCG agonist efinopegdutide (10 mg) reduced liver fat by 72.7%, compared to 42.3% with semaglutide (1 mg) despite similar WLindicating potential weight-independent effects of GCG on hepatic steatosis [40]
Study: Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk
Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death